Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 148 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acne/Rosacea Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Cutera Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment

NCT03424304
View directory record Official record
Conditions
Wrinkle, Rosacea, Scarring
Interventions
Excel V™ Laser With Green Genesis
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 27, 2026, 5:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 21 Day Pharmacokinetics Study in Papulopustular Rosacea

NCT02028286
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
CLS001
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
2
States / cities
Hackensack, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 27, 2026, 5:55 PM EDT
Completed Phase 2 Interventional Results available

Open Label Pilot Study of Apremilast in Treatment of Rosacea

NCT01045551
View directory record Official record
Conditions
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Interventions
Apremilast
Drug
Lead sponsor
Julian M. Mackay-Wiggan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 27, 2026, 5:55 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Intralesional Tetracycline Injection in the Treatment of Chalazia

NCT01763437
View directory record Official record
Conditions
Chalazia, Chalazion
Interventions
Tetracycline
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 27, 2026, 5:55 PM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Acne

NCT04214483
View directory record Official record
Conditions
Acne, Acne Vulgaris, Acne Keloidalis, Acne Keloid, Acne Conglobata, Acne Rosacea, Acne Inversa, Acne Cystic, Acne Pomade, Acne Indurata, Acne Papular, Acne Tropica, Acne Urticata, Acne Fulminans, Acne Follicular, Acne Tropicalis, Acne Detergicans, Acne Iodide, Acne Varioliformis
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 27, 2026, 5:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pulsed Dye Laser (PDL) vs. Microsecond 1064-nm Nd:YAG Laser for Treatment of Diffuse Facial Redness

NCT01529996
View directory record Official record
Conditions
Rosacea
Interventions
Pulse Dye Laser/YAG laser
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 27, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea

NCT03287791
View directory record Official record
Conditions
Rosacea
Interventions
Generic Azelaic Acid Foam, Finacea® (Azelaic Acid) Foam, Vehicle Foam, Cleanser, Sunscreen, Towel, Moisturizing Lotion
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
26
States / cities
Encino, California • La Mesa, California • Brandon, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 27, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

NCT03276936
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
FMX103 1.5%
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
79
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 72 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 27, 2026, 5:55 PM EDT
Completed No phase listed Observational

Preferences & Treatment Satisfaction Drivers in Rosacea Patients

NCT02602470
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251), Azelaic Acid Cream, Metronidazole gel, Metronidazole cream, Metronidazole Emulsion, Metronidazole Lotion, Brimonidine Tartrate Gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 27, 2026, 5:55 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea

NCT00823901
View directory record Official record
Conditions
Rosacea
Interventions
Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel, Placebo gel
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 27, 2026, 5:55 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

NCT06952517
View directory record Official record
Conditions
Papular-pustular Rosacea, Papulopustular Rosacea (PPR), Papulopustular Rosacea
Interventions
Clascoterone Cream 1%
Drug
Lead sponsor
Narrows Institute for Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 27, 2026, 5:55 PM EDT
Completed Phase 2 Interventional

DMT210 Topical Gel in the Treatment of Acne Rosacea

NCT03003104
View directory record Official record
Conditions
Acne Rosacea
Interventions
DMT210 Topical Gel 5%, Vehicle Control
Drug · Other
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
9
States / cities
San Diego, California • Miami, Florida • Fridley, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 27, 2026, 5:55 PM EDT
Completed Not applicable Interventional

The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea

NCT03392558
View directory record Official record
Conditions
Rosacea
Interventions
Burt's Bees Skin Care Regimen, Control Regimen
Other
Lead sponsor
Burt's Bees Inc.
Industry
Eligibility
25 Years to 60 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 27, 2026, 5:55 PM EDT
Completed Phase 2 Interventional Results available

Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%

NCT00697541
View directory record Official record
Conditions
Erythematous Rosacea
Interventions
0.18% COL-118 facial gel (1.8 mg brimonidine), 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop), Advanced Eye Relief, COL-118 facial gel vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 27, 2026, 5:55 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea

NCT06072066
View directory record Official record
Conditions
Rosacea, Systemic Inflammation
Interventions
Skin Barrier Oral Supplement
Dietary Supplement
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
30 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 27, 2026, 5:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea

NCT05616923
View directory record Official record
Conditions
Rosacea, Erythematotelangiectatic
Interventions
Trametinib
Drug
Lead sponsor
Albany Research Institute, Inc.
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Oct 27, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

NCT02289352
View directory record Official record
Conditions
Rosacea
Interventions
Brimonidine, placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
16
States / cities
Hot Springs, Arkansas • Long Beach, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 27, 2026, 5:55 PM EDT
Completed Phase 2 Interventional

The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage

NCT00991198
View directory record Official record
Conditions
Rosacea, Acne Vulgaris, Atopic Dermatitis, Seborrheic Dermatitis
Interventions
Topical oxygen, placebo
Drug
Lead sponsor
Aria Aesthetics Inc.
Industry
Eligibility
25 Years to 60 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 27, 2026, 5:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea

NCT04153188
View directory record Official record
Conditions
Erythematotelangiectatic Rosacea
Interventions
The Vbeam® Prima System, Oxymetazoline HCL 1% Cream
Device · Drug
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 27, 2026, 5:55 PM EDT
Not listed Phase 2 Interventional

DMT310-005 Topical in the Treatment of Acne Rosacea

NCT05108025
View directory record Official record
Conditions
Acne Rosacea
Interventions
Topical Powder, Placebo Topical Powder
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 27, 2026, 5:55 PM EDT
Completed No phase listed Observational

An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%

NCT00668655
View directory record Official record
Conditions
Rosacea
Interventions
Metronidazole Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
20 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 27, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties

NCT05675501
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Encapsulated Benzoyl Peroxide Cream
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 27, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT04608500
View directory record Official record
Conditions
Facial Papulopustular Rosacea
Interventions
FMX103 minocycline foam 1.5%, Vehicle foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
46
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 27, 2026, 5:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety and Efficacy of the Luxe Device to Treat Facial Wrinkles and Rosacea

NCT01618864
View directory record Official record
Conditions
Rosacea, Wrinkles
Interventions
Luxe
Device
Lead sponsor
Syneron Medical
Industry
Eligibility
21 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 27, 2026, 5:55 PM EDT